TECH-MAHINDRA
19.9.2023 16:35:36 CEST | Business Wire | Press release
Tech Mahindra, a leading provider of digital transformation, consulting, and business re-engineering services & solutions, today inaugurated a local innovation centre in Espoo, Finland. This expansion comes after a sustained period of growth in the region and signifies Tech Mahindra’s commitment to further its journey in Finland, and the Nordic region. The new centre will accommodate a diverse workforce – increasing the in-country headcount ranging from experienced business leaders to fresh talent, in collaboration with the local ecosystem.
Located in Espoo, a part of the greater Helsinki metropolitan area, the new centre situates Tech Mahindra at the heart of one of the major business hotspots and innovation hubs in the Nordics. From this strategic location, Tech Mahindra will continue to provide digital business transformation services and solutions to customers.
Mohit Joshi, Managing Director and CEO Designate of Tech Mahindra, said, “Given its focus on innovation, sustainability, and a unique approach to entrepreneurship; today Finland ranks amongst the topmost countries in the world that leverage emerging technologies to shape the future business landscape. This is also reflected in Tech Mahindra’s commitment to the ongoing expansion in the Nordics region, and the establishment of our new centre in Espoo. It is our endeavor to widen the talent pool, fuel innovation, improve agility to deliver robust solutions, and be closer to our customers’ businesses to drive sustainable growth.”
The inauguration ceremony was attended by dignitaries such as Raveesh Kumar, Ambassador of India to Finland; Jusa Susia, Senior Director & Head of Region East Asia & India at Business Finland; and Janne Kari, Head of Industry, ICT and Digitalisation at Invest in Finland. Tech Mahindra representatives include CP Gurnani, Managing Director and CEO; Mohit Joshi, Managing Director and CEO Designate; Mukul Dhyani, Senior Vice President & Business Head Continental Europe; Rajesh Barwal, VP & Country Manager for Sweden and Finland; C-H Hallstrom, Vice President, Strategic Programs, Nordics.
Further to the commitment in 2022 to set up a Makers Lab, Tech Mahindra’s research and development arm in Finland, the newly opened centre will also facilitate innovation in collaboration with new and existing customers in the region. The team will work on new and emerging technologies such as Quantum computing, Generative AI and Metaverse. The Makers Lab will also plug into the local startup ecosystem and universities to provide new opportunities in R&D across industries.
In the ten years since Tech Mahindra entered the Finnish market, the organisation has firmly established itself as a leading business transformation expert in the region. By leveraging deep industry expertise and long-term experience in tailoring and deploying best-in-class solutions, Tech Mahindra continues to help businesses to navigate the complex challenges present in the modern business landscape.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230919543874/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release
Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release
“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
FIFA and Fanatics Expand Wide-Ranging Relationship to Include Historic Exclusive Collectibles Agreement (Trading Cards, Stickers and Trading Card Games)7.5.2026 13:00:00 CEST | Press release
Partnership includes FIFA tournaments and events from 2031Agreement encompasses both physical and digital collectibles, and for the first time brings the player jersey patch program to international footballPre-match press conferences for the FIFA World Cup Final to take place at Fanatics Fest on Friday, 17 July 2026 In a landmark agreement expanding their already successful wide-ranging commercial relationship, FIFA and Fanatics have signed a long-term, exclusive collectibles licensing deal that features trading cards, stickers, and trading card games. The agreement, which will begin in full in 2031, covers both physical and digital collectibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507105628/en/ An example of the product innovations that will be brought to fans under this new partnership is the highly sought-after player jersey patch program, including debut patches, which will be inserted into football tradin
DEFINITIVE Trial Reaches Major Milestone: All Centres Approved and More Than 50% Recruitment Achieved7.5.2026 11:21:00 CEST | Press release
Poster presented at ESMO Breast Cancer 2026: Exploring health policy and real-world treatment strategies for early-stage HER2-positive breast cancer across Europe. The DEFINITIVE project, a landmark European Union-funded international phase III clinical trial evaluating the use of the HER2DX diagnostic assay to guide personalised treatment in early-stage HER2-positive breast cancer (BC), announces two major operational milestones at the ESMO Breast Cancer 2026 congress. Approvals have been obtained in the 7 participating countries, 33 clinicals sites are now open for patient recruitment. The trial has reached over 50% of its recruitment target, marking a pivotal moment on the path toward to transforming HER2-positive BC treatment. About the DEFINITIVE Project The DEFINITIVE project is a 5-year, prospective, open-label, randomised, two-arm phase III international clinical trial conducted across 44 centres in 7 European member states and associated countries. The trial aims to demonstrat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom